£136.74
0.45% yesterday
London, Dec 24, 03:30 pm CET
ISIN
GB0009895292
Symbol
AZN

AstraZeneca Stock price

£136.74
-2.60 1.87% 1M
+34.14 33.27% 6M
+34.28 33.46% YTD
+34.59 33.86% 1Y
+31.31 29.69% 3Y
+72.33 112.30% 5Y
+103.39 310.00% 10Y
+123.86 961.42% 20Y
London, Closing price Wed, Dec 24 2025
-0.62 0.45%
ISIN
GB0009895292
Symbol
AZN
Industry

New AI Insights on AstraZeneca Insights AI Insights on AstraZeneca

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
£211.3b
Enterprise Value
£229.4b
Net debt
£18.1b
Cash
£6.1b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
30.8 | 19.8
P/S
4.9 | 4.7
EV/Sales
5.3 | 5.1
EV/FCF
32.4
P/B
6.2
Dividends
DPS
£2.46
Yield 1Y | 5Y
1.8% | 2.5%
Growth 1Y | 5Y
7.8% | 2.4%
Payout 1Y | 3Y
73.8% | 92.4%
Increased
1 Year
Financials (TTM | estimate)
Revenue
£43.1b | £44.6b
EBITDA
£13.5b | £15.9b
EBIT
£10.5b | £14.1b
Net Income
£7.0b | £10.8b
Free Cash Flow
£7.1b
Growth (TTM | estimate)
Revenue
13.5% | 11.3%
EBITDA
20.9% | 29.9%
EBIT
26.1% | 49.7%
Net Income
44.7% | 106.5%
Free Cash Flow
41.6%
Margin (TTM | estimate)
Gross
81.9%
EBITDA
31.3% | 35.7%
EBIT
24.3%
Net
16.2% | 24.1%
Free Cash Flow
16.5%
Financial Health
Equity Ratio
39.2%
Return on Equity
17.3%
ROCE
17.6%
ROIC
14.8%
Debt/Equity
0.7
More
EPS
£4.5
FCF per Share
£4.6
Short interest
-
Employees
94k
Rev per Employee
£420.0k
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

28x Buy
85%
4x Hold
12%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

Buy
85%
Hold
12%
Sell
3%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
43,071 43,071
14% 14%
100%
- Direct Costs 7,797 7,797
15% 15%
18%
35,274 35,274
13% 13%
82%
- Selling and Administrative Expenses 11,735 11,735
5% 5%
27%
- Research and Development Expense 10,125 10,125
18% 18%
24%
13,496 13,496
21% 21%
31%
- Depreciation and Amortization 3,011 3,011
6% 6%
7%
EBIT (Operating Income) EBIT 10,485 10,485
26% 26%
24%
Net Profit 6,964 6,964
45% 45%
16%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Positive
Proactive Investors
about 14 hours ago
The festive period is, for some, a time for taking stock of what's happened in the past year - for others, though, its a time to pick stocks for the year ahead. So it is, then, that it's the season for looking ahead.
Negative
WSJ
3 days ago
The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.
Negative
Reuters
3 days ago
AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung cancer.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today